Failure to recognize and respond to how rapidly illegal drug markets have changed with the arrival of illegally manufactured synthetic opioids will continue to put many Americans at risk of exposure to fentanyl, endangering the lives of hundreds of thousands more for years to come.
For decades, elected officials brushed off harm reduction as a viable option for reducing the harms of drug use over concerns of enabling drug consumption. But now, these strategies are front and center, spoken aloud, from the largest podium in the land, and during prime time. What caused this historic about-face?
Synthetic opioids are likely to increasingly reach illegal drug markets. Failure to recognize and respond to how rapidly drug markets have changed with the arrival of illegally manufactured synthetic opioids will continue to put many at risk of exposure to fentanyl, endangering the lives of hundreds of thousands more Americans for years to come.
Some communities hard hit by the opioid crisis are interested in opening supervised consumption sites—places where people who use drugs can do so under supervision of trained staff. What could be done to make it easier to pilot and evaluate these sites in the United States?
Australia is at risk of a fentanyl problem, but it is better prepared than North America. If the country can make the same kind of concerted effort it did to keep COVID-19 at bay, that could save thousands of lives.
After counties in South Dakota implemented a 24/7 sobriety program, repeat arrests for impaired driving decreased in the counties by an average of 12%. North Dakota implemented a similar program and also saw decreases in impaired driving. Can the same results be achieved outside of the Dakotas?
Despite the many clinical trials that have demonstrated the effectiveness and safety of treatments for alcohol use disorder, we still know little about whether men and women respond differently to treatment. Without knowing whether recommended treatments are effective for women, women are vulnerable to the consequences of alcohol misuse.
Policymakers can wield a multitude of tools to address vaping-related illness. Cannabis policy reform is one option. But policymakers may face challenges in balancing comprehensive regulatory design that promotes product safety with its potential to bolster the illegal and unregulated market.
A global settlement with pharmaceutical companies has started to appear more and more likely. Even with billions of dollars, the settlement resources won't be unlimited. To avoid mistakes made in the tobacco master settlement agreement, any opioid funds must be carefully allocated.
Although opioid prescriptions in the U.S. have fallen, opioid overdose deaths remain at historic levels. The continued spread of fentanyl and other illicitly manufactured synthetic opioids suggests the problem could still get worse.
Marijuana policy is a growing topic of discussion, and laws are starting to change. Ten choices confronting jurisdictions considering legalization cover many of the critical decisions that will determine whether removing prohibition is a good idea.
Currently, evidence for the safety, harmfulness, utility, and addictiveness of e-cigarettes is lacking. The questions that research needs to answer, however, are clear as day—particularly since business is booming.